Venetoclax Combined with Azacytidine Can Be a First-line Treatment Option for Elderly Blastic Plasmacytoid Dendritic Cell Neoplasm
Authors:
Open Access
- 1 September 2023
- journal article
- research article
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 62 (17) , 2547-2551
Abstract
An 84-year-old Japanese man was diagnosed with blastic plasmacytoid dendritic cell neoplasm (BPDCN). We administered combination therapy using venetoclax and azacytidine. We observed neutropenia (Grade 4), thrombocytopenia (Grade 2), and stomatitis (Grade 3). After six cycles of treatment, the BPDCN abnormal cells in the bone marrow specimen almost disappeared, and atypical cells were not detected in a skin biopsy. We propose venetoclax combined with azacytidine as a useful treatment approach in elderly patients, although clinicians should be mindful that therapeutic modifications may be essential to minimize and/or avoid adverse events.Keywords
This publication has 14 references indexed in Scilit:
- Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemiaBlood, 2019
- Clinical experience with the BCL2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignanciesAmerican Journal of Hematology, 2017
- Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to VenetoclaxCancer Discovery, 2017
- Azacitidine in the treatment of blastic plasmacytoid dendritic cell neoplasm: a report of 3 casesLeukemia & Lymphoma, 2016
- Blastic plasmacytoid dendritic cell neoplasm: the first report of two cases treated by 5‐AzacytidineEuropean Journal of Haematology, 2014
- Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasmLeukemia, 2013
- Blastic plasmacytoid dendritic cell neoplasm (BPDCN): the cutaneous sanctuary.2012
- Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter studyHaematologica, 2012
- CD4+/CD56+ Hematodermic TumorAmerican Journal of Clinical Pathology, 2007
- CD4+ CD56+ lineage negative malignancies: a new entity developed from malignant early plasmacytoid dendritic cells.2003